| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0e2eed5536697b43563caf4d793d7696 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-47
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-47 |
| filingDate |
2005-03-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a85a447ae824bd25b5d110979de7c327 |
| publicationDate |
2007-10-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2007244152-A1 |
| titleOfInvention |
Use of an Nk3 Antagonist for the Treatment of Bipolar Disorders |
| abstract |
This invention relates to the use of the NK3 receptor antagonist talnetant [(S)—(−)—N-(α-ethylbenzyl)-3-hydroxy-2-phenylquinoline-4-carboxamide] for treating bipolar disorder. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8962612-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9884057-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10844434-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11219617-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AU-2017201900-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2012027491-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11179378-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11173153-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10869861-B2 |
| priorityDate |
2004-03-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |